Pacific Biosciences of California, Inc. Share Price
Stocks
PACB
US69404D1081
Advanced Medical Equipment & Technology
|
Real-time Estimate
Cboe BZX
01:29:51 29/09/2026 am IST
|
5-day change | 1st Jan Change | ||
| 1.715 USD | +5.86% |
|
+27.93% | -6.96% |
| Market Cap | 50Cr 44Cr 42Cr 38Cr 71Cr 4.83TCr 72Cr 501.42Cr 193.65Cr 2.47TCr 189.05Cr 184.96Cr 7.93TCr | P/E 2026 * |
-3.68x | P/E 2027 * | -3.49x |
|---|---|---|---|---|---|
| Enterprise Value | 97Cr 86Cr 81Cr 73Cr 137.73Cr 9.33TCr 138.53Cr 968.13Cr 373.9Cr 4.76TCr 365.02Cr 357.11Cr 15TCr | EV / Sales 2026 * |
6.12x | EV / Sales 2027 * | 5.58x |
| Free-Float |
91.09% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| PACB | Delayed | |
CBOE
| PACB | Real-time | |
|
Tradegate
| P09 | Real-time | |
|
Boerse Muenchen
| P09 | Real-time | |
|
Deutsche Boerse AG
| P09 | Delayed | |
|
Börse Stuttgart
| P09 | Delayed |
Last Transcript: Pacific Biosciences of California, Inc.
| 1 day | +7.40% | ||
| 1 week | +27.93% | ||
| Current month | +28.40% | ||
| 1 month | +24.27% | ||
| 3 months | +0.57% | ||
| 6 months | +38.08% | ||
| Current year | -6.96% |
| 1 week | 1.36 |  | 1.8 |
| 1 month | 1.25 | | 1.8 |
| Current year | 1.07 | | 2.73 |
| 1 year | 1.07 | | 2.73 |
| 3 years | 0.85 | | 10.65 |
| 5 years | 0.85 | | 31.1 |
| 10 years | 0.85 | | 53.69 |
| Manager | Title | Age | Since |
|---|---|---|---|
Mark van Oene
CEO | Chief Executive Officer | 53 | 05/08/2026 |
Jim Gibson
DFI | Director of Finance/CFO | 57 | 31/03/2025 |
Jonas Korlach
CTO | Chief Tech/Sci/R&D Officer | - | 01/07/2012 |
| Director | Title | Age | Since |
|---|---|---|---|
Bill Ericson
BRD | Director/Board Member | 67 | 01/01/2004 |
Randy Livingston
BRD | Director/Board Member | 72 | 01/01/2009 |
Marshall Mohr
BRD | Director/Board Member | 69 | 18/01/2012 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 17/08/26 | Sell | Chief Executive Officer | -26,911 | 0.0087% | ||
| 10/08/26 | Free | Chief Executive Officer | 24,57,018 | 0.7911% | ||
| 03/06/26 | Free | Chairman | 2,23,492 | 0.0720% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +5.86% | +27.93% | +39.18% | -79.19% | 50Cr | |
| +0.94% | +3.06% | +46.93% | +34.96% | 25TCr | |
| +1.31% | +5.42% | +22.29% | -7.95% | 16TCr | |
| +2.12% | +3.17% | -5.66% | +39.92% | 14TCr | |
| -0.66% | +0.57% | -54.69% | -17.61% | 6.37TCr | |
| +0.71% | -1.55% | +12.67% | +24.31% | 4.97TCr | |
| +1.47% | +8.18% | +41.57% | +56.42% | 4.87TCr | |
| +2.33% | +2.38% | -14.54% | -18.18% | 4.79TCr | |
| +2.28% | +4.46% | +53.00% | +60.83% | 4.26TCr | |
| +0.71% | +13.46% | +194.94% | +104.73% | 4.08TCr | |
| Average | +1.90% | +5.92% | +33.57% | +19.83% | 8.44TCr | |
| Weighted average by Cap. | +1.27% | +4.22% | +27.38% | +26.02% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 16Cr 14Cr 13Cr 12Cr 23Cr 1.53TCr 23Cr 158.23Cr 61Cr 778.32Cr 60Cr 58Cr 2.5TCr | 18Cr 16Cr 15Cr 14Cr 26Cr 1.77TCr 26Cr 183.56Cr 71Cr 902.91Cr 69Cr 68Cr 2.9TCr |
| Net income | -14Cr -12Cr -12Cr -11Cr -20Cr -1.35TCr -20Cr -140.01Cr -54Cr -688.7Cr -53Cr -52Cr -2.21TCr | -14Cr -13Cr -12Cr -11Cr -20Cr -1.37TCr -20Cr -142.49Cr -55Cr -700.9Cr -54Cr -53Cr -2.25TCr |
| Net Debt | 47Cr 41Cr 39Cr 35Cr 66Cr 4.5TCr 67Cr 466.71Cr 180.25Cr 2.3TCr 175.96Cr 172.15Cr 7.38TCr | 52Cr 46Cr 44Cr 40Cr 74Cr 5.04TCr 75Cr 522.33Cr 201.73Cr 2.57TCr 196.93Cr 192.67Cr 8.26TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/26/29 | $1.735 | +7.10% | 1,91,86,589 |
| 25/26/25 | $1.620 | +2.53% | 1,13,67,889 |
| 24/26/24 | $1.580 | +12.06% | 1,11,00,917 |
| 23/26/23 | $1.410 | -4.08% | 52,57,416 |
| 22/26/22 | $1.470 | +8.09% | 78,48,551 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- PACB Stock
Select your edition
All financial news and data tailored to specific country editions
